Abstract : Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later.
https://hal-pasteur.archives-ouvertes.fr/pasteur-01579663
Contributor : Anne Lassailly-Bondaz
<>
Submitted on : Thursday, August 31, 2017 - 2:54:58 PM
Last modification on : Saturday, March 30, 2019 - 7:46:05 PM
Long-term archiving on : Friday, December 1, 2017 - 6:30:00 PM
Eva Hong, Aude Terrade, Muhamed-Kheir Taha. Human Vaccines & Immunotherapeutics Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine. Human vaccines & immunotherapeutics. (Hum Vaccin Immunother), 2015-: Philadelphia, PA : Taylor & Francis, 2016, ⟨10.1080/21645515.2016.1241358⟩. ⟨pasteur-01579663⟩
